The Value of βTG/PF4 Ratio in Patients with High Platelet Count – Reply

AbstractUncontrolled diabetes has been associated with progression of diabetic retinopathy (DR) in several studies. Therefore, we aimed to investigate systemic and ophthalmic factors related to worsening of DR even after completion of panretinal photocoagulation (PRP). We retrospectively reviewed DR patients who had completed PRP in at least one eye with a 3-year follow-up. A total of 243 eyes of 243 subjects (mean age 52.6 ± 11.6 years) were enrolled. Among them, 52 patients (21.4%) showed progression of DR after PRP (progression group), and the other 191 (78.6%) patients had stable DR (non-progression group). The progression group had higher proportion of proliferative DR (P = 0.019); lower baseline visual acuity (P < 0.001); and higher platelet count (P = 0.048), hemoglobin (P = 0.044), and hematocrit, (P = 0.042) than the non-progression group. In the multivariate logistic regression analysis for progression of DR, baseline visual acuity (HR: 0.053, P < 0.001) and platelet count (HR: 1.215, P = 0.031) were identified as risk factors for progression. Consequently, we propose that patients with low visual acuity or high platelet count are more likely to have progressive DR despite PRP and require careful observation. Also, the evaluation of hemorheological factors including platelet counts before PRP can be considered useful in predicting the prognosis of DR.

Download Full-text

Immobilization and high platelet count are associated with thromboembolic complications in heparin-induced thrombocytopenia

Pharmacoepidemiology and Drug Safety ◽

10.1002/pds.4235 ◽

2017 ◽

Vol 26 (10) ◽

pp. 1149-1155 ◽

Cited By ~ 3

Author(s):

Juliane Bolbrinker ◽

Edeltraut Garbe ◽

Antonios Douros ◽

Matthias Huber ◽

Elisabeth Bronder ◽

...

Keyword(s):

Platelet Count ◽

Thromboembolic Complications ◽

Heparin Induced Thrombocytopenia ◽

High Platelet Count

Download Full-text

Pretreatment platelet count predicts survival outcome of patients with de novo non-M3 acute myeloid leukemia

PeerJ ◽

10.7717/peerj.4139 ◽

2017 ◽

Vol 5 ◽

pp. e4139 ◽

Cited By ~ 6

Author(s):

Qianying Zhang ◽

Kanchun Dai ◽

Laixi Bi ◽

Songfu Jiang ◽

Yixiang Han ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

Platelet Count ◽

Predictive Value ◽

Myeloid Leukemia ◽

De Novo ◽

Univariate Analysis ◽

Survival Outcome ◽

Cox Regression Analysis ◽

High Platelet Count ◽

Acute Myeloid

Background Pretreatment platelet count has been reported as a potential tool to predict survival outcome in several solid tumors. However, the predictive value of pretreatment platelet count remains obscure in de novo acute myeloid leukemia (AML) excluding acute promyelocytic leukemia (M3). Methods We conducted a retrospective review of 209 patients with de novo non-M3 AML in our institute over a period of 8 years (2007–2015). Receiver operating characteristic (ROC) curve analysis was used to determine the optimal platelet (PLT) cutoff in patients. We analyzed the overall survival (OS) and disease free survival (DFS) using the log-rank test and Cox regression analysis. Results By defining the platelet count 50 × 109/L and 120 × 109/L as two cut-off points, we categorized the patients into three groups: low (<50 × 109/L), medium (50–120 × 109/L) and high (>120 × 109/L). On univariate analysis, patients with medium platelet count had longer OS and DFS than those with low or high platelet count. However, the multivariate analysis showed that only longer DFS was observed in patients with medium platelet count than those with low or high platelet count. Conclusion Our findings indicate that pretreatment platelet count has a predictive value for the prognosis of patients with non-M3 AML.

Download Full-text